Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

<i>Background</i>: NK cell-based immunotherapy to prevent relapse after allogeneic transplantation is an appealing strategy because NK cells can provide strong antitumor effect without inducing graft-versus-host disease (GVHD). Thus, we designed a phase-I clinical trial evaluating the sa...

Full description

Bibliographic Details
Main Authors: Raynier Devillier, Boris Calmels, Sophie Guia, Mohammed Taha, Cyril Fauriat, Bechara Mfarrej, Geoffroy Venton, Eric Vivier, Daniel Olive, Christian Chabannon, Didier Blaise, Sophie Ugolini
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
allogeneic hematopoietic stem cell transplantation
cellular immunotherapy
IL-2-activated NK cells
antitumor immunity
Online Access:https://www.mdpi.com/2072-6694/13/11/2673

Internet

https://www.mdpi.com/2072-6694/13/11/2673

Similar Items